RESOURCE AND PATIENT MANAGEMENT SYSTEM

Clinical Reporting System

(BGP)

Addendum to User Manual

Version 11.1 Patch 1
November 2011

Office of Information Technology (OIT)
Division of Information Resource Management
Albuquerque, New Mexico

Table of Contents

Revision History

Date	Revision	Description	Author
05/31/2011	N/A	Skeleton draft.	J. Kimberly
07/27/2011	0.1	Revisions for Patch 1 Build T1 content.	A.M. Brough
09/13/2011	1.0	Revisions for Builds T2, T3 and T4.	J. Kimberly

1.0 Introduction

Patch 1 provides enhancements to version11.1 of the Clinical Reporting System software (namespace BGP).

Please review these changes and add a copy of them to any printed documentation your site may be using for the Clinical Reporting System Version 11.1. These changes will be integrated into future version of the software and user manual and will no longer be considered an addendum at the time of the next release.

1.1 Summary of Changes

Patch 1 of the Clinical Reporting System Version 11.1 contains the changes listed below. There are no logic changes to existing performance measures for any report.

Added new 2011 Eligible Professional (EP) Clinical Quality Measures Reports.

2.0 Patch 1 Details

2.1 Expanded Stage 1 Meaningful Use Eligible Professional (EP) Clinical Quality Measures Report

Expansion of the Stage 1 Meaningful Use Eligible Provider Clinical Quality Measure Report for a selected reporting period, using the performance measure logic released in CRS version 11.0 Patch 2. This report now includes logic for all 44 Eligible Provider Clinical Quality Measures.

For instructions on running this report, please follow the steps in Section 2.3.

Performance Measure	**Denominator(s)**	**Numerator(s)** (documented in past year, unless defined otherwise)
Asthma Assessment (NQF 0001)	Patients who reach 5–40 years of age during the reporting period with a diagnosis of asthma who had at least 2 office or outpatient consultation encounters with the EP during the reporting period.	Patients who were assessed for or had active asthma daytime and nighttime symptoms before or simultaneously to the latest encounter with the EP occurring during the reporting period.
Appropriate Testing for Children with Pharyngitis (NQF 0002)	Patients 2–18 years of age with at least 1 ED or outpatient encounter with the EP during the reporting period who were diagnosed with pharyngitis during this encounter and who were prescribed an antibiotic by the EP during or within 3 days after the encounter.	Patients who had a group A streptococcus (strep) laboratory test performed <= 3 days before or <= 3 days after the pharyngitis antibiotics were prescribed or dispensed. These antibiotics are aminopenicillins; beta-lactamase inhibitors; first, second, and third generation cephalosporins; folate antagonists; lincomycin derivatives; macrolides; miscellaneous antibiotics; natural penicillins; penicillinase-resistant penicillins; quinolones; sulfonamides and tetracycline.
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement (NQF 0004)	Denominator 1: Patients 13-17 years old who have at least 1 of the following with the EP from 1 year before to 45 days before the reporting period end date which will be defined as the FIRST diagnosis of alcohol or drug dependence for use in Numerator 1: 1. A FIRST diagnosis of alcohol or drug dependence during an emergency department (ED) encounter, an acute or non-acute	Numerator 1: Patients who meet at least 1 of the following conditions which will be defined as the FIRST TREATMENT for use in Numerator 2: 1. A FIRST acute or non-acute inpatient encounter with an alcohol, drug rehab and detoxification intervention with the EP from 1 year before to 45 days before the reporting period end date. Please note: this is the same as denominator condition 2 above.

Performance Measure	Denominator(s)	Numerator(s) (documented in past year, unless defined otherwise)
	inpatient encounter, an outpatient behavioral health (BH) or an outpatient BH req point of service (POS) encounter with a POS modifier. 2. A FIRST acute or non-acute inpatient encounter with an alcohol, drug rehab and detoxification intervention. 3. A FIRST detoxification intervention. Additionally, patients must not have had a diagnosis of alcohol or drug dependence <= 60 days BEFORE the FIRST episode described in conditions 1, 2 and 3 above. Denominator 2: Patients 18+ who meet the conditions listed in denominator 1. Denominator 3: Patients 13+ who meet the conditions listed in denominator 1.	2. An acute or non-acute inpatient encounter, an outpatient BH encounter or an outpatient BH req encounter with a POS modifier <= 14 days and a diagnosis of alcohol or drug dependence after the FIRST diagnosis of alcohol or drug dependence as defined in the denominator. Numerator 2: Patients who had at least 2 counts of any of the following <= 30 days after the FIRST TREATMENT as defined in numerator 1: 1. Acute or non-acute inpatient encounters with a diagnosis of alcohol or drug dependence 2. Outpatient BH encounters 3. Outpatient BH req POS encounters with a POS modifier and a diagnosis of alcohol or drug dependence
Prenatal Care: Screening for HIV (NQF 0012)	Patients who had live birth delivery with at least 1 prenatal encounter during the reporting period.	Patients whose estimated date of conception was less than or equal to 10 months from live birth delivery who received HIV screening within 30 days of first or second prenatal encounter during the reporting period.
Prenatal Care: Anti-D Immune Globulin (NQF 0014)	D (Rh) negative, unsensitized patients who gave birth during the measurement period and had at least 1 prenatal encounter with the EP.	Patients whose estimated date of conception was ≤10 months before birth who were given anti-d immune globulin at or between 26-32 weeks gestation.

Performance Measure	**Denominator(s)**	**Numerator(s)** (documented in past year, unless defined otherwise)
Controlling High Blood Pressure (NQF 0018)	Patients 18-85 years of age who during the reporting period had an active diagnosis of hypertension and at least 1 outpatient encounter with the EP and none of the following: --Active diagnosis of pregnancy --Active diagnosis of End Stage Renal Disease (ESRD) --Procedures indicative of ESRD	Patients whose lowest systolic BP reading was < 140 mmHg and lowest diastolic BP reading was < 90 mmHg during their most recent outpatient encounter with the EP during the reporting period.
Smoking and Tobacco Use Cessation, Medical assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies (NQF 0027)	Patients 18+ with 1 or more outpatient encounters with the EP within 2 years of the reporting period end date.	Numerator 1: Patients who were tobacco users within 1 year of the reporting period end date. Numerator 2: Patients who were tobacco users who received tobacco use cessation counseling within 1 year of the reporting period end date.
Chlamydia Screening for Women (NQF 0033)	Denominator 1: Patients 15-24 who had at least 1 outpatient encounter with the EP on or before the reporting period end date AND at least one of the following: --During the reporting period: 1. Procedure indicative of sexually active women 2. Laboratory test (either performed or with a result) for pregnancy 3. Pregnancy encounter OR --On or before the reporting period end date: 4. Lab tests indicative of a sexually active woman 5. Diagnosis of a sexually active woman 6. Prescription for contraceptives 7. Use of an IUD device 8. Allergy to an IUD device 9. Contraceptive use education	Patients with a laboratory test performed for chlamydia screening during the reporting period.

Performance Measure	Denominator(s)	Numerator(s) (documented in past year, unless defined otherwise)
	Denominator 2: Patients 15-19 years old who had at least 1 outpatient encounter with the EP during the reporting period AND at least one of the conditions numbered 1 through 9 listed in denominator 1. Denominator 3: Patients 20-24 years old who had at least 1 outpatient encounter with the EP during the reporting period AND at least one of the conditions numbered 1 through 9 listed in denominator 1.	
Meds for Asthma (NQF 0036)	Denominator 1: Patients 5-11 years old who meet at least 1 of the following conditions: 1. At least 1 emergency department (ED) or acute inpatient encounter with the EP during the reporting period or within 1 year before the beginning of the reporting period AND an active diagnosis of asthma during this timeframe. 2. At least 4 outpatient encounters with the EP during the reporting period or within 1 year before the beginning of the reporting period AND an active diagnosis of asthma during this timeframe AND 2 counts of asthma medication prescribed during this timeframe. These asthma medications are defined as antiasthmatic combinations, antibody inhibitors, inhaled corticosteroids, inhaled steroid combinations, leukotriene inhibitors, long- and short-acting inhaled beta 2 agonists, mast cell stabilizers and methylxanthines. 3. At least 4 counts of asthma	Patients who were prescribed at least 1 count of asthma medication during the reporting period. These asthma medications are defined as antiasthmatic medication combinations, antibody inhibitor, inhaled corticosteroids, inhaled steroid combinations, leukotriene inhibitors, mast cell stabilizers, and methylxanthines.

Performance Measure	Denominator(s)	Numerator(s) (documented in past year, unless defined otherwise)
	medication prescribed by the EP during the reporting period or within 1 year before the beginning of the reporting period. These asthma medications are defined as antiasthmatic combinations, antibody inhibitors, inhaled corticosteroids, inhaled steroid combinations, long- and short-acting inhaled beta 2 agonists, mast cell stabilizers and methylxanthines. 4. At least 4 counts of leukotriene inhibitor medication prescribed by the EP during the reporting period or within 1 year before the beginning of the reporting period AND an active diagnosis of asthma during this timeframe. Denominator 2: Patients 12-50 years old who meet at least one of the conditions numbered 1 through 4 listed in denominator 1. Denominator 3: Patients 5-50 years old who meet at least one of the conditions numbered 1 through 4 listed in denominator 1.	
Pneumonia Vaccination Status for Older Adults (NQF 0043)	Patients who reach 65 years of age or older during the reporting period with at least 1 outpatient encounter with the EP within 1 year of the reporting period end date.	Patients who received a pneumococcal vaccine on or before the reporting period end date.
Asthma Pharmacologic Therapy (NQF 0047)	Patients 5–40 with an active diagnosis of mild, moderate, or severe persistent asthma on or before the reporting period end date and who had at least 2 office and outpatient consultation encounters with the EP during the reporting period..	Patients who were prescribed an inhaled corticosteroid or alternative asthma medication including short- and long-acting-inhaled beta2 agonists, leukotriene modifiers, and theophylline classes during the reporting period.
Low Back Pain: Imaging Studies (NQF 0052)	Patients 18-49 who had an active diagnosis of low back pain	Patients who did not have any spinal imaging done within 28 days after the

Performance Measure	**Denominator(s)**	**Numerator(s)** (documented in past year, unless defined otherwise)
	occurring during an emergency department, outpatient, orthopedic, or chiropractic encounter with the EP during the reporting period and who DID NOT HAVE any of the following: --Previous diagnosis of low back pain within 180 days BEFORE the FIRST diagnosis of low back pain during the reporting period --Diagnosis of cancer, trauma, IV drug abuse, or neurologic impairment within 2 years of the reporting period end date	first diagnosis of low back pain during the reporting period.
Diabetes Measures: Eye Exam (NQF 0055)	Patients who reach 18–75 years of age during the reporting period with at least 1 of the following within 2 years of the reporting period end date: --Dispensed, ordered or active medications indicative of diabetes prescribed by the EP --An active diagnosis of diabetes with at least 1 of the following with the EP during the reporting period: --1 acute inpatient or ED encounter --2 non-acute inpatient, outpatient, or ophthalmology encounters on different dates	Patients who had an eye exam during the reporting period OR had both an eye exam and no active diagnosis of diabetic retinopathy during the year prior to the reporting period.
Diabetes: Foot Exam (NQF 0056)	Patients who reach 18–75 years of age during the reporting period with at least 1 of the following within 2 years of the reporting period end date: --Dispensed, ordered or active medications indicative of diabetes prescribed by the EP --An active diagnosis of diabetes with at least one of the following with the EP during the reporting period: --1 acute inpatient or ED encounter --2 non-acute inpatient, outpatient, or ophthalmology encounters on different dates	Patients who had a foot exam during the reporting period.

Performance Measure	**Denominator(s)**	**Numerator(s)** (documented in past year, unless defined otherwise)
Diabetes: Hemoglobin A1c Poor Control (NQF 0059)	Patients who reach 18–75 years of age during the reporting period with at least 1 of the following within 2 years of the reporting period end date: --Dispensed, ordered or active medications indicative of diabetes prescribed by the EP --An active diagnosis of diabetes with at least 1 of the following with the EP during the reporting period: --1 acute inpatient or ED encounter --2 non-acute inpatient, outpatient, or ophthalmology encounters on different dates	Patients who had an HbA1c test during the reporting period with the most recent result value being > 9.0%.
Diabetes: Blood Pressure Management (NQF 0061)	Patients who reach 18–75 years of age during the reporting period with at least 1 of the following within 2 years of the reporting period end date: --Dispensed, ordered or active medications indicative of diabetes prescribed by the EP --An active diagnosis of diabetes with at least 1 of the following with the EP during the reporting period: --1 acute inpatient or ED encounter --2 non-acute inpatient, outpatient, or ophthalmology encounters on different dates	Patients whose lowest blood pressure reading during their most recent encounter with the EP during the reporting period was systolic < 140 mmHg and diastolic < 90 mmHg.
Diabetes: Urine Screening (NQF 0062)	Patients who reach 18–75 years of age during the reporting period with at least 1 of the following within 2 years of the reporting period end date: --Dispensed, ordered or active medications indicative of diabetes prescribed by the EP --An active diagnosis of diabetes with at least one of the following with the EP during the reporting period: --1 acute inpatient or ED encounter	Patients who had a nephropathy screening test or evidence of nephropathy during the reporting period, or patients who were treated with ACE inhibitors/ARBs.

Performance Measure	Denominator(s)	Numerator(s) (documented in past year, unless defined otherwise)
	--2 non-acute inpatient, outpatient, or ophthalmology encounters on different dates	
Diabetes: LDL Management and Control (NQF 0064)	Patients who reach 18–75 years of age during the reporting period with at least 1 of the following within 2 years of the reporting period end date: --Dispensed, ordered or active medications indicative of diabetes prescribed by the EP --An active diagnosis of diabetes with at least 1 of the following with the EP during the reporting period: --1 acute inpatient or ED encounter --2 non-acute inpatient, outpatient, or ophthalmology encounters on different dates	Numerator 1: Patients who had an LDL-C test during the reporting period. Numerator 2: Patients who had LDL-C test during the reporting period with the most recent result value < 100mg/dL.
Diabetes: Hemoglobin A1c Control (NQF 0575)	Patients who reach 18–75 years of age during the reporting period with at least 1 of the following within 2 years of the reporting period end date: --Dispensed, ordered or active medications indicative of diabetes prescribed by the EP --An active diagnosis of diabetes with at least 1 of the following with the EP during the reporting period: --1 acute inpatient or ED encounter --2 non-acute inpatient, outpatient, or ophthalmology encounters on different dates	Patients who had an HbA1c test during the reporting period with the most recent result value being < 8.0%.
Coronary Artery Disease (CAD): Oral Antiplatelet Therapy (NQF 0067)	Patients 18+ with at least 2 outpatient encounters or 2 nursing facility encounters or 1 inpatient encounter with the EP during the reporting period AND a diagnosis of CAD (includes myocardial infarction (MI)) or a cardiac surgery procedure on or before any of the encounter dates.	Patients who were prescribed oral antiplatelet therapy during the reporting period.
Coronary Artery Disease	Patients who reach 18+ with at	Patients who were prescribed beta-

Performance Measure	**Denominator(s)**	**Numerator(s)** (documented in past year, unless defined otherwise)
(CAD): Beta-Blocker Therapy (NQF 0070)	least 2 outpatient encounters or 2 nursing facility encounters or 1 inpatient encounter with the EP during the reporting period AND who had the following on or before any of these encounters: --an active diagnosis of CAD or a cardiac surgery procedure, and –-a prior diagnosis of MI.	blocker therapy during the reporting period.
Coronary Artery Disease (CAD): Drug Therapy for LDL-Cholesterol (NQF 0074)	Patients 18+ with at least 2 outpatient or 2 nursing facility encounters with the EP during the reporting period AND a diagnosis of CAD (includes myocardial infarction (MI)) or a cardiac surgery procedure on or before any of the encounter dates.	Patients who were prescribed lipid-lowering therapy during the reporting period.
Ischemic Vascular Disease: BP Management (NQF 0073)	Patients 18+ with either of the following: --At least 1 acute inpatient encounter with the EP 14-24 months prior to the reporting period end date and any of the following: --Percutaneous transluminal coronary angioplasty (PTCA) 14-24 months prior to the reporting period end date --Diagnosis of Acute myocardial infarction (AMI) during this encounter --Coronary artery bypass graft (CABG) 14-24 months prior to the reporting period end date --At least 1 acute inpatient or outpatient encounter with the EP within 2 years of the reporting period end date with a diagnosis of ischemic vascular disease (IVD) during this encounter.	Patients whose lowest systolic BP reading was < 140 mmHg and lowest diastolic BP reading was < 90 mmHg during their most recent acute inpatient or outpatient encounter with the EP before the end of the reporting period.
Ischemic Vascular Disease: Lipid Panel and LDL Control (NQF 0075)	Patients 18+ with either of the following: --At least 1 acute inpatient encounter with the EP 14-24 months prior to the reporting period end date with any of the following: --Percutaneous transluminal	Numerator 1: Patients who had either an LDL test OR had all of the following during the reporting period: --High density lipoprotein (HDL) test --Total cholesterol test --Triglycerides test

Performance Measure	Denominator(s)	Numerator(s) (documented in past year, unless defined otherwise)
	coronary angioplasty (PTCA) 14-24 months prior to the reporting period end date --Acute myocardial infarction (AMI) during this encounter --Coronary artery bypass graft (CABG) 14-24 months prior to the reporting period end date --At least 1 acute inpatient or outpatient encounter with the EP within 2 years of the reporting period end date with a diagnosis of ischemic vascular disease (IVD) during this encounter.	Numerator 2: Patients who had an LDL test with the most recent result value < 100mg/dL OR had both of the following during the reporting period: --Triglycerides test with the most recent value < 400 mg/dL --(Most recent total cholesterol test value minus most recent HDL test value minus most recent triglycerides test value) divided by 5 < 100mg/dL
Ischemic Vascular Disease: Use of Aspirin/Antithrombotic(NQF 0068)	Patients who reach 18 years of age and older during the reporting period with either of the following: --At least 1 acute inpatient encounter with the EP 14-24 months prior to the reporting period end date and any of the following: --Percutaneous transluminal coronary angioplasty (PTCA) 14-24 months prior to the reporting period end date --Acute myocardial infarction (AMI) during this encounter --Coronary artery bypass graft (CABG) 14-24 months prior to the reporting period end date --At least 1 acute inpatient or outpatient encounter with the EP with a diagnosis of ischemic vascular disease (IVD) within 2 years of the reporting period end date.	Patients who were prescribed oral antiplatelet therapy or had documented use of aspirin or an alternative antithrombotic therapy during the reporting period.
Heart Failure: ACEI or ARB for LVSD (NQF 0081)	Patients 18+ with at least 1 inpatient discharge encounter OR at least 2 outpatient encounters OR 2 nursing facility encounters with the EP during the reporting period AND a diagnosis of heart failure during or before any of these encounters AND a LVEF of < 40% before the latest of these encounters.	Patients who were prescribed ACE inhibitors or ARB medications by the EP during the reporting period.
Heart Failure: Beta-	Patients 18+ with at least 2	Patients who were prescribed beta-

Performance Measure	Denominator(s)	Numerator(s) (documented in past year, unless defined otherwise)
Blocker Therapy for LVSD (NQF 0083)	outpatient encounters or 2 nursing facility encounters with the EP during the reporting period AND a diagnosis of heart failure during or before any of these encounters, AND a LVF assessment study result of < 40% OR an ejection fraction result of < 40% before the latest of these encounters.	blocker medication by the EP during the reporting period.
Heart Failure: Warfarin Therapy Patients with A-Fib (NQF 0084)	Patients 18+ with at least 2 outpatient or nursing facility encounters with the EP during the reporting period AND a diagnosis of heart failure on or before the encounters AND a diagnosis of atrial fibrillation before or during the reporting period.	Patients who were prescribed warfarin therapy during the reporting period.
Primary Open Angle Glaucoma: Optic Nerve Eval (NQF 0086)	Patients 18+ with at least 2 of any of the following: domiciliary, nursing facility, office & outpatient consulting, or ophthalmological service encounters with the EP during the reporting period and a diagnosis of POAG on or before any of these encounters.	Patients who had at least 1 optic nerve head evaluation procedure during a domiciliary, nursing facility, office & outpatient consulting, or ophthalmological service encounter with the EP during the reporting period.
Diabetic Retinopathy: Macular Edema and Severity of Retinopathy (NQF 0088)	Patients 18+ with 2 or more office & outpatient consult, ophthalmological services, nursing facility, or domiciliary encounters with the EP during the reporting period AND a diagnosis of diabetic retinopathy during or before any of these encounters.	Patients who had a macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during 1 or more encounters with the EP during the reporting period.
Diabetic Retinopathy: Communication with Diabetes Care Physician (NQF 0089)	Patients 18+ with 2 or more office & outpatient consultation, ophthalmological services, nursing facility, or domiciliary encounters with the EP during the reporting period AND a diagnosis of diabetic retinopathy during or before the latest of these encounters AND a dilated macular or fundus exam performed during at least of 1 of these encounters.	Patients who had documented communication to the provider who manages the ongoing care of the diabetic patient regarding the findings of the macular or fundus exam at least once on or after the macular or fundus exam during the reporting period.
Antidepressant Medication Management: (a) Effective Acute Phase Treatment,	Patients 18+ as of 245 days on or before the reporting period end date with an	Numerator 1: Patients who had at least 1 active or expired prescription of antidepressant

Performance Measure	**Denominator(s)**	**Numerator(s)** (documented in past year, unless defined otherwise)
(b)Effective Continuation Phase Treatment (NQF 0105)	active/dispensed/ordered antidepressant medication <= 30 days before or <= 14 days after the FIRST diagnosis of major depression. AND WITH one of the following: --a FIRST primary diagnosis of major depression during at least 1 of the following encounters with the EP between <= 245 days before the reporting period start date and => 245 days before the reporting period end date: emergency department (ED), outpatient behavioral health (BH), or outpatient BH req point of service (POS) with a POS modifier. --a FIRST secondary diagnosis of major depression during at least 2 of the following encounters with the EP between <= 245 days before the reporting period start date and => 245 days before the reporting period end date: ED, outpatient BH, or outpatient BH req POS with a POS modifier. --a FIRST secondary diagnosis of major depression during at least 1 of the following encounters with the EP between <= 245 days before the reporting period start date and => 245 days before the reporting period end date: acute inpatient or non-acute inpatient. AND WITHOUT an active diagnosis of major depression or depression <= 120 days on or before the FIRST active diagnosis of major depression identified above.	medication for a duration of => 84 days after the FIRST diagnosis of major depression as identified in the denominator. Numerator 2: Patients who had at least 1 active or expired prescription of antidepressant medication for a duration of => 180 days after the FIRST diagnosis of major depression as identified in the denominator.
Colon Cancer: Chemo for Stage III (NQF 0385)	Patients 18+ with at least 2 office visit encounters with the EP during the reporting period AND a diagnosis of colon cancer or an inactive colon cancer history during or before any of these	Patients who have been prescribed or been administered adjuvant chemotherapy for colon cancer during or before any of the office visit encounters with the EP during the measurement reporting period.

Performance Measure	Denominator(s)	Numerator(s) (documented in past year, unless defined otherwise)
	encounters AND a colon cancer stage III procedure result during or before any of these encounters.	
Breast Cancer: Hormonal Therapy for Stage IC-IIIC ER/PR (NQF 0387)	Female patients 18+ with at least 2 office visit encounters with the EP during the reporting period AND a diagnosis of Stage IC–IIIC, ER or PR positive breast cancer during or before any of these encounters.	Female patients who were prescribed tamoxifen or aromatase inhibitor AI therapy during the reporting measurement period.
Prostate Cancer Low Risk: Avoidance of Bone Scan Overuse (NQF 0389)	Patients with at least 1 office visit encounter with the EP during the reporting period with an active diagnosis of prostate cancer before or during the reporting period AND who had a prostate cancer treatment during the reporting period AND who had all of the following before or simultaneously to the prostate cancer treatment: –-Procedure results of AJCC cancer stage low risk recurrence --Prostate specific antigen test result of <=10 mg/dL --Gleason score result <=6	Patients who did not have a diagnostic bone scan study performed on or after the date of the prostate cancer diagnosis.

Table 2-1: Content of the 35 New Eligible Professional (EP) Clinical Quality Measure Topics

2.2 Running the Eligible Professional (EP) Meaningful Use Report

Logging into CRS and Accessing the Eligible Professional Meaningful Use Menus

For detailed instructions on logging into CRS and accessing the Eligible Professional Meaningful Use menus for your location, please refer to Section 4.2 of the CRS Version 11.0 User Manual.

For detailed instructions on running the Meaningful Use Eligible Provider Clinical Quality Performance Measures report, please refer to Section 2.3 of the CRS Version 11.0 Patch 2 User Manual Addendum.

The Meaningful Use reports do not verify that the Eligible Provider selected for the reports meets the CMS EHR Incentive Program eligibility criteria. The Eligible Provider must make that determination.

Contact Information

If you have any questions or comments regarding this distribution, please contact the OIT Help Desk (IHS).

Phone: (505) 248-4371 or (888) 830-7280 (toll free)

Fax: (505) 248-4363

Web: http://www.ihs.gov/GeneralWeb/HelpCenter/Helpdesk/index.cfm

Email: support@ihs.gov